Baculovirus-expressed influenza vaccine

Bibliography

• COUCH RB: Prevention and treatment of influenza. N. Engl. J. Med. (2000) 343:1778-1787.
   PubMed Web of Science ®Google Scholar
• SAFDAR A, ARMSTRONG D: Infectious morbidity in critically ill patients with cancer. Crit. Care Clin. (2001) 17:531-570.
   PubMed Web of Science ®Google Scholar
• COUCH RB: Influenza, influenza virus vaccine, and human immunodeficiency virus infection. Clin. Infect. Dis. (1999) 28:548-551.
   PubMed Web of Science ®Google Scholar
• ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES; SMITH NM, BRESEE JS, SHAY DK, UYEKI TM, COX NJ, STRIKAS RA: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Recomm. Rep. (2006) 55:1-42.
   Google Scholar
• MUNOZ FM, GALASSO GJ, GWALTNEY JM et al.: Current research on influenza and other respiratory viruses: II International Symposium. Antiviral Res. (2000) 46:91-124.
   PubMed Web of Science ®Google Scholar
• KROON FP, VAN DISSEL JT, DE JONG JC, VAN FURTH R: Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS (1994) 8:469-476.
   PubMed Web of Science ®Google Scholar
• GANDHI MK, EGNER W, SIZER L et al.: Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant. (2001) 28:775-781.
   PubMed Web of Science ®Google Scholar
• ROBERTSON JD, NAGESH K, JOWITT SN et al.: Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenza type B in patients with multiple myeloma. Br. J. Cancer (2000) 82:1261-1265.
   PubMed Web of Science ®Google Scholar
• HERRERA GA, IWANE MK, CORTESE M et al.: Influenza vaccine effectiveness among 50 – 64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, US, 2003 – 2004. Vaccine (2007) 25(1):154-160.
   PubMed Web of Science ®Google Scholar
• LO W, WHIMBEY E, ELTING L, COUH R, CABANILLAS F, BODEY G: Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur. J. Clin. Microbiol. Infect. Dis. (1993) 12:778-782.
   PubMed Web of Science ®Google Scholar
• LJUNGMAN P, NAHI H, LINDE A: Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br. J. Haemtol. (2005) 130:96-98.
   PubMed Web of Science ®Google Scholar
• RAPEZZI D, STICCHI L, RACCHI O, MANGERINI R, FERRARIS AM, GAETANI GF: Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma. Eur. J. Haematol. (2003) 70:225-230.
   PubMed Web of Science ®Google Scholar
• MOSTOW SR, DOWDLE WR, SCHOENBAUM SC, COLEMAN MT, KAYE HS: Inactivated vaccines. I. Volunteer studies with very high doses of influenza vaccine purifies by zonal ultracentrifugation. Postgrad. Med. J. (1973) 49:152-158.
   PubMed Web of Science ®Google Scholar
• PARKMAN PD, HOPPS HE, RASTOGI SC, MEYER HM Jr: Summary of clinical trials of influenza virus vaccines in adults. J. Infect. Dis. (1977) 136:S722-S730.
   PubMed Web of Science ®Google Scholar
• LAKEY DL, TREANOR JJ, BETTS RF et al.: Recombinant Baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J. Infect. Dis. (1996) 174:838-841.
   PubMed Web of Science ®Google Scholar
• TREANOR JJ, SCHIFF GM, COUCH RB et al.: Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J. Infect. Dis. (2006) 193:1223-1228.
   PubMed Web of Science ®Google Scholar
• KEITEL WA, ATMAR RL, CATE TR et al.: Safety of high dose of influenza vaccine and effect on antibody responses in elderly persons. Arch. Intern. Med. (2006) 166:1121-1127.
   PubMed Web of Science ®Google Scholar
• SAFDAR A, RODRIGUEZ MA, FAYAD LE et al.: Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin's lymphoma. J. Infect. Dis. (2006) 194:1394-1397.
   PubMed Web of Science ®Google Scholar
• COX MMJ, ANDERSON KD: Production of novel influenza vaccine using insect cells: protection against drifted strains. Influenza and Other Respiratory Viruses (2007) 1:35-40.
   PubMed Web of Science ®Google Scholar
• HOLTZ, KM, ANDERSON DK, COX MMJ: Production of a recombinant influenza vaccine using the baculovirus expression vector system. Bioprocess J. (2003) 2(5):65-73.
   Google Scholar
• WANG K, HOLTZ KM, ANDERSON K, CHUBET R, MAHMOUD W, COX MM: Expression and purification of an influenza hemagglutinin – one step closer to a recombinant protein-based influenza vaccine. Vaccine (2006) 24:2176-2185.
   PubMed Web of Science ®Google Scholar
• LAMB RA: Genes and proteins of the influenza viruses. In: The Influenza Viruses. Krug RM (Ed.), Plenum Press, New York, USA (1989):1-87.
   Google Scholar
• KILBOURNE ED, CERINI CP, KHAN MW, MITCHELL JW Jr, OGRA PL: Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J. Immunol. (1987) 138:3010-3013.
   PubMed Web of Science ®Google Scholar
• MURPHY BR, KASEL JA, CHANOCK RM: Association of serum anti-neuraminidase antibody with resistance to influenza in man. N. Engl. J. Med. (1972) 286:1329-1332.
   PubMed Web of Science ®Google Scholar
• DEROO T, JOU WM, FIERS W: Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine (1996) 14:561-569.
   PubMed Web of Science ®Google Scholar
• JOHANSSON BE, PRICE PM, KILBOURNE ED: Immunogenicity of influenza virus N2 neuraminidase produced in insect larvae by baculovirus recombinants. Vaccine (1995) 13:841-845.
   PubMed Web of Science ®Google Scholar
• KILBOURNE ED, POKORNY BA, JOHANSSON B, BRETT I, MILEV Y, MATTHEWS JT: Protection of mice with recombinant influenza virus neuraminidase. J. Infect. Dis. (2004) 189:459-461.
   PubMed Web of Science ®Google Scholar
• MATTHEWS J: Preclinical and clinical evaluation of a purified, baculovirus-expressed influenza neuraminidase antigen. The Baculovirus & Insect Cell Culture Conference. San Antonio, USA (21 – 24 February 2000).
   Google Scholar
• PINTO LH, HOLSINGER LJ, LAMB RA: Influenza virus M2 protein has ion channel activity. Cell (1992) 69:517-528.
   PubMed Web of Science ®Google Scholar
• SUGRUE RJ, HAY AJ: Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology (1991) 180:617-624.
   PubMed Web of Science ®Google Scholar
• ITO T, GORMAN OT, KAWAOKA Y, BEAN WJ, WEBSTER RG: Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J. Virol. (1991) 65:5491-5498.
   PubMed Web of Science ®Google Scholar
• ZEBEDEE SL, LAMB RA: Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol. (1988) 62:2762-2772.
   PubMed Web of Science ®Google Scholar
• TREANOR JJ, TIERNEY EL, ZEBEDEE SL, LMB RA, MURPHY BR: Passively transferred monoclonal antibodies to the M2 protein inhibits influenza A virus replication in mice. J. Virol. (1990) 64:1375-1377.
   PubMed Web of Science ®Google Scholar
• SLEPUSHKIN VA, KATZ JM, BLACK RA, GAMBLE WC, ROTA PA, COX NJ: Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine (1995) 13:1399-1402.
   PubMed Web of Science ®Google Scholar
• BLACK RA, ROTA PA, GORODKOVA N, KLENK HD, KENDAL AP: Antibody responses of the M2 protein of influenza A virus expressed in insect cells. J. Gen. Virol. (1993) 74:143-146.
   PubMed Web of Science ®Google Scholar
• KASS I, ARKIN IT: How pH opens a H+ channel: the gating mechanism of influenza A M2. Structure (2005) 13:1789-1798.
   PubMed Web of Science ®Google Scholar
• PINTO LH, LAMB RA: The M2 proton channels of influenza A and B viruses. J. Biol. Chem. (2006) 281:8997-9000.
   PubMed Web of Science ®Google Scholar
• HAY AJ, WOLSTENHOLME AJ, SKEHEL JJ, SMITH MH: The molecular basis of the specific anti-influenza action of amantadine. EMBO J. (1985) 4:3021-3024.
   PubMed Web of Science ®Google Scholar
• LAMB RA, KRUG RM: Orthomyxoviridae: the viruses and their replication. In: Fields Virology. Knipe DM, Howley PM (Eds), Lippincott Williams & Wilkins, Philadelphia, USA (2001) 4:1487-1531.
   Google Scholar
• FRACE AM, KLIMOV AI, ROWE T, BLACK RA, KATZ JM: Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine (1999) 17:2237-2244.
   PubMed Web of Science ®Google Scholar
• NEIRYNCK S, DEROO T, SAELENS X, VANLANDSCHOOT P, JOU WM, FIERS W: A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. (1999) 5:1157-1163.
   PubMed Web of Science ®Google Scholar
• FAN J, LIANG X, HORTON MS et al.: Preclinical study of influenza virus A M2 peptide conjugate vaccine in mice, ferrets, and rhesus monkeys. Vaccine (2004) 22:2993-3003.
   PubMed Web of Science ®Google Scholar
• HEINEN PP, RIJSEWIJK FA, DE BOER-LUIJTZE EA, BIANCHI ATJ: Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J. Gen. Virol. (2002) 83:1851-1859.
   PubMed Web of Science ®Google Scholar
• HIEN TT, DE JONG M, FARRAR J: Avian influenza – a challenge to global health care structure. N. Engl. J. Med. (2004) 351:2363-2365.
   PubMed Web of Science ®Google Scholar
• STEPHENSON I, NICHOLSON KG, WOOD JM, ZAMBON MC, KATZ JM: Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet (2004) 4:499-509.
   PubMed Web of Science ®Google Scholar
• TREANOR JJ, CAMPBELL JD, ZANGWILL KM, ROWE T, WOLFF M: Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. (2006) 354:1343-1351.
   PubMed Web of Science ®Google Scholar
• CRAWFORD J, WILKINSON BE, VOSNESENSKY A et al.: Baculovirus-derived rHA vaccines protect against lethal influenza infections by avian H5 & H7 subtypes. Vaccine (1999) 17:2265-2274.
   PubMed Web of Science ®Google Scholar
• TREANOR JJ, WILKINSON BE, MASSEOUD F et al.: Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans vaccine. Vaccine (2001) 19:1732-1737.
   PubMed Web of Science ®Google Scholar